Last reviewed · How we verify

ACT-293987 — Competitive Intelligence Brief

ACT-293987 (ACT-293987) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Soluble guanylate cyclase (sGC) stimulator. Area: Pulmonary Hypertension / Fibrosis.

phase 3 Soluble guanylate cyclase (sGC) stimulator Soluble guanylate cyclase (sGC) Pulmonary Hypertension / Fibrosis Small molecule Live · refreshed every 30 min

Target snapshot

ACT-293987 (ACT-293987) — Actelion. ACT-293987 is a selective soluble guanylate cyclase (sGC) stimulator that increases intracellular cGMP levels to promote vasodilation and reduce fibrosis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ACT-293987 TARGET ACT-293987 Actelion phase 3 Soluble guanylate cyclase (sGC) stimulator Soluble guanylate cyclase (sGC)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Soluble guanylate cyclase (sGC) stimulator class)

  1. Actelion · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ACT-293987 — Competitive Intelligence Brief. https://druglandscape.com/ci/act-293987. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: